Ipamorelin and CJC-1295 have had a complicated 18 months in US regulatory terms. In September 2024, the FDA removed both from the Category 2 restricted list — not because they were moved to Category 1 (compoundable), but because the nominators who had originally submitted them for review withdrew their nominations (FDA PCAC briefing document, 2024). That created a regulatory limbo: no longer prohibited via Category 2, but not explicitly permitted via Category 1 either.
The February 2026 announcement from HHS Secretary RFK Jr. changed that outlook. Approximately 14 of the 19 previously Category 2 peptides are expected to return to Category 1 status — restoring clear 503A compounding access with a physician's prescription. Ipamorelin and CJC-1295 are among those expected to benefit (Oath Peptides, 2026). The regulatory picture in April 2026 is: compounding may be legally available through some pharmacies now, and is likely to be formally confirmed as Category 1 in the near future.
Key Takeaways
- —Both ipamorelin and CJC-1295 were removed from FDA Category 2 in September 2024 and are expected to be confirmed as Category 1 compoundable under RFK Jr.'s February 2026 reclassification.
- —The only safe access route remains a licensed physician's prescription through a USP <797>-compliant compounding pharmacy — not research peptide vendors.
- —Teichman et al. (2006) is the key human data: CJC-1295 raised GH 2–10× and IGF-1 0.5–3× sustained for 9–11 days post-injection.
- —Compare ipamorelin and CJC-1295 mechanisms and dosing with the Next Pep comparison tool before your first consultation.
The September 2024 Category 2 removal created practical uncertainty for both compounding pharmacies and prescribers. With the compounds neither explicitly permitted (Category 1) nor explicitly prohibited (Category 2), compounding pharmacies took different positions — some continued dispensing based on the removal from the restricted list, others paused pending clearer guidance.
What the February 2026 announcement means practically: the PCAC (Pharmacy Compounding Advisory Committee) review process is expected to formally add these compounds to Category 1 before mid-2026. Until that formal listing, some pharmacies will compound under the RFK announcement as guidance; others may wait for the official Category 1 listing. If you're seeking access now, ask the pharmacy explicitly what regulatory basis they're compounding on.
These two compounds work on different receptors and are almost always used together — which is why they're typically sold and discussed as a stack. Understanding what each does separately matters for quality verification.
Ipamorelin is a pentapeptide GHRP (growth hormone releasing peptide) — MW 711.85 Da, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It binds GHS-R1a (the ghrelin receptor) in the pituitary. Its selectivity is its key property: at 200× its effective dose, it did not significantly elevate ACTH or cortisol in preclinical studies — a profile no earlier GHRP achieved (Raun et al., 1998). Half-life approximately 2 hours.
CJC-1295 (with or without DAC) is a 30-amino-acid GHRH analogue. The DAC (Drug Affinity Complex) version uses a lysine-maleimide conjugation that enables albumin binding, extending half-life from minutes to 6–8 days. A single CJC-1295 DAC injection raised plasma GH 2–10× and IGF-1 0.5–3× for 9–11 days post-injection in the Teichman 2006 phase I/II human trial — the primary human evidence for this compound class (PubMed, Teichman et al., 2006).
Each compound has specific molecular identity markers that mass spectrometry must confirm.
For ipamorelin: Theoretical MW 711.85 Da. HPLC purity ≥98%. The COA should specify ipamorelin (not a generic "GHRP") and confirm MW within ±0.5 Da. Given ipamorelin's selectivity profile, any contaminant that's a structurally similar GHRP (e.g., GHRP-2, GHRP-6) could confound results — purity matters here beyond just the percentage.
For CJC-1295 without DAC: Theoretical MW approximately 3,295 Da. This form has a much shorter half-life than the DAC form (minutes vs. days). It's typically used in daily dosing protocols to produce discrete pulsatile GH releases.
For CJC-1295 with DAC: Theoretical MW approximately 3,368 Da. This is the form Teichman studied — weekly dosing is possible because albumin binding extends the half-life dramatically. The MW difference from the non-DAC form is small but mass spectrometry should confirm which you're receiving, since the pharmacokinetics and dosing frequency differ completely.
Third-party lab verification — the same standard as all research peptides applies: named independent laboratory, verifiable report ID, lot-specific documentation, current test date.
Even in the current uncertain regulatory environment, the clinical access pathway for ipamorelin + CJC-1295 involves a licensed prescriber and a compounding pharmacy. The quality of that prescriber relationship matters.
Baseline lab work. At minimum, a prescriber should order IGF-1 (the primary efficacy endpoint — the Teichman data uses this as the main endpoint), fasting glucose and insulin (GH is counter-regulatory to insulin), and thyroid function (GH influences T4→T3 conversion). Providers who prescribe without baseline IGF-1 can't tell you whether the protocol is working.
Understanding of the DAC vs. non-DAC distinction. CJC-1295 with DAC (weekly dosing, 6–8 day half-life) and CJC-1295 without DAC (daily dosing, minutes half-life) produce fundamentally different GH profiles. The Teichman 2006 trial used the DAC form. A prescriber conflating the two, or a pharmacy dispensing one when the prescription specifies the other, is a quality failure.
Monitoring for glucose dysregulation. Growth hormone is physiologically counter-regulatory to insulin — GH elevation reduces insulin sensitivity acutely. At the doses used in ipamorelin + CJC-1295 protocols, the effect is modest, but fasting glucose should be checked periodically in any patient with existing glucose management concerns.
The ipamorelin research profile and the in-depth ipamorelin + CJC-1295 guide cover the dual-receptor synergy, the Teichman 2006 data, the FDA 2024 Category 2 history, and full dosing tables. Reading both before your prescriber consultation means you can engage with the clinical detail rather than relying entirely on the provider's summary. The peptide library gives you the complete GH secretagogue class — ipamorelin, CJC-1295, sermorelin, and others — in structured, citation-backed format in one place.
If you want to compare this stack against sermorelin — a simpler GHRH analogue with a longer approval history — the comparison tool puts all three side by side. And when you have a protocol, the dosing calculator handles the reconstitution for both compounds: enter your vial concentration and target dose and it returns exact draw volume in mL and syringe units. Next Pep is the independent research reference — not a pharmacy, not a telehealth platform, and not a vendor.
The regulatory position as of April 2026: both were removed from FDA Category 2 in September 2024, and the RFK Jr. February 2026 announcement indicates they're expected to be formally added to Category 1 (compoundable) shortly. Some compounding pharmacies are dispensing now based on the Category 2 removal; others await the formal Category 1 listing. Ask your pharmacy specifically what regulatory basis they're using. With a physician's prescription and a compliant pharmacy, access is available in most US states.
CJC-1295 with DAC (Drug Affinity Complex) includes a maleimide group that enables covalent albumin binding, extending the half-life to 6–8 days per injection. One weekly injection maintains sustained GH elevation. CJC-1295 without DAC has a half-life of minutes — it's used in daily dosing protocols to create discrete pulsatile GH pulses, often timed around training or sleep. The Teichman 2006 human evidence used the DAC form. Both have distinct dosing implications and the compounding pharmacy prescription must specify which version.
The Teichman 2006 data showed sustained IGF-1 elevation within 9–11 days of a single CJC-1295 injection. For a standard protocol where the goal is IGF-1 optimisation, a follow-up IGF-1 lab test at 8–12 weeks of consistent dosing gives the most interpretable data. IGF-1 has slow response kinetics — single time-point measurements within the first few weeks aren't reliable protocol indicators.
CJC-1295 + ipamorelin is synergistic because they activate different receptor systems — GHRHR (growth hormone releasing hormone receptor) via CJC-1295 and GHS-R1a (ghrelin receptor) via ipamorelin. Dual receptor activation produces a larger GH pulse than either alone. CJC-1295 alone produces sustained baseline GH elevation; ipamorelin adds a selective pulsatile component. Most published clinical protocols and the practitioner data use the combination, not CJC-1295 as a standalone.
This article is for research and educational purposes only. Ipamorelin and CJC-1295 require a licensed physician's prescription for legal compounding access. Regulatory status is evolving — verify current FDA Category 1/2 status before initiating any protocol. Consult a qualified healthcare professional before starting any growth hormone secretagogue protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.